Some　genetic　alterations　of　glutathione　S-transferase　omega　2　(GSTO2)　have　been　reported　to　increase　the　risk　of　many　malignancies,　including　hepatocellular　carcinoma　(HCC);　however,　their　prognostic　capability　remained　unresolved　in　HCC　patients　treated　with　transarterial　chemoembolization　(TACE).　To　fill　this　gap,　we　genotyped　three　well-defined　polymorphisms　in　GSTO2　to　assess　whether　they　can　predict　overall　survival　among　228　HCC　patients　under　TACE　treatment.　The　median　follow-up　time　and　survival　time　were　22.0　months　(range　3.0-60.0)　and　19.2　months,　respectively.　Only　one　of　three　polymorphisms　examined,　rs157077,　was　significantly　associated　with　overall　survival　of　TACE-treated　HCC　(P　=　0.003),　and　its　mutant　allele　conferred　a　higher　risk　of　death　than　its　wild　homozygotes　(hazard　ratio　1.58,　95　%　confidence　interval　1.17-2.14).　Moreover,　carriers　of　this　mutant　allele　had　higher　tissue　GSTO2　expression,　reinforcing　the　prognostic　capability　of　GSTO2　rs157077　for　HCC,　especially　in　combination　with　age　and　tumor-node-metastasis　(TNM)　stage.　Taken　together,　we　for　the　first　time　provided　evidence　supporting　the　prognostic　role　of　GSTO2　in　the　progression　of　TACE-treated　HCC.